Midatech Pharma (NASDAQ:MTP) Trading Up 4%

Midatech Pharma PLC-ADR (NASDAQ:MTP)’s stock price was up 4% during mid-day trading on Friday . The stock traded as high as $1.30 and last traded at $1.30, approximately 42 shares changed hands during trading. A decline of 100% from the average daily volume of 58,655 shares. The stock had previously closed at $1.25.

Separately, ValuEngine upgraded shares of Midatech Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

The firm’s fifty day moving average price is $1.37 and its 200-day moving average price is $1.32. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.05. The company has a market cap of $3.86 million, a P/E ratio of -2.83 and a beta of 2.81.

A hedge fund recently bought a new stake in Midatech Pharma stock. Morgan Stanley bought a new stake in shares of Midatech Pharma PLC-ADR (NASDAQ:MTP) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 50,000 shares of the company’s stock, valued at approximately $72,000. Morgan Stanley owned approximately 1.63% of Midatech Pharma as of its most recent filing with the SEC. Institutional investors own 4.86% of the company’s stock.

About Midatech Pharma (NASDAQ:MTP)

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.

Featured Story: What is a Leveraged Buyout (LBO)?

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.